Cor Vasa 2018, 60(3):e215-e223 | DOI: 10.1016/j.crvasa.2017.09.007

Increased dose of diuretics correlates with severity of heart failure and renal dysfunction and does not lead to reduction of mortality and rehospitalizations due to acute decompensation of heart failure; data from AHEAD registry

Marie Pavlušováa,b, Roman Miklíka,b, Radim Špačekc, Klára Benešovád, Kamil Zemanc, Alain Cohen-Solale,f,g, Alexandre Mebazaae,f,h, Simona Littnerovád, Marián Felšöcia, Ludmila Pohludkovác, Ladislav Dušekd, Lenka Špinarovái, Jiří Vítoveci, Jindřich Špinara,b, Jiří Jarkovskýd,*, Jiří Pařenicaa,b
a Interní kardiologická klinika, Fakultní nemocnice Brno, Brno, Česká republika
b Lékařská fakulta Masarykovy univerzity, Brno, Česká republika
c Interní oddělení, Nemocnice ve Frýdku-Místku, Frýdek-Místek, Česká republika
d Institut biostatistiky a analýz, Lékařská fakulta Masarykovy univerzity, Brno, Česká republika
e UMR-S 942 INSERM, Lariboisière Hospital, Assistance Publique-Hôpitaux de Paris, Paříž, Francie
f Paris Diderot University, Sorbonne Paris Cité, Paříž, Francie
g Department of Cardiology, Lariboisière Hospital, Assistance Publique-Hôpitaux de Paris, Paříž, Francie
h Department of Anaesthesiology and Critical Care, Lariboisière Hospital, Assistance Publique-Hôpitaux de Paris, Paříž, Francie
i I. interní kardioangiologická klinika, Fakultní nemocnice u sv. Anny v Brně, Brno, Česká republika

Background: Diuretics are being used to reduce symptoms of congestion and fluid retention in heart failure patients but their effect has not been studied in randomized clinical trials. The data about positive or negative effect of loop diuretics depending on their dose is conflicting and controversial. The aim of this analysis is to evaluate whether the relatively small increase in the dose of furosemide can reduce the incidence of readmissions for acute heart failure decompensation and/or total mortality.

Methods and results: We evaluated a total of 1119 patients admitted for ADHF who were discharged from the hospital back home in a stable condition. All surviving patients were followed up for at least two years. The primary endpoint was a combination of hospital readmissions for acute heart failure and overall mortality. The primary analysis showed significantly different characteristics and prognosis of patients who did not require any loop diuretic and those requiring furosemide dose >125 mg. Therefore, we compared a group of patients with low-dose furosemide (10-40 mg) with a group of patients with high-dose furosemide (41-125 mg) only. The higher dose of diuretics correlated well with disease severity (lower systolic blood pressure, more frequent chronic exertional dyspnea NYHA III, lower left ventricular ejection fraction, increased creatinine levels). Long-term mortality and the number of rehospitalizations were lower in the low-dose diuretic group (p = 0.037 and p = 0.036, respectively) but after adjustment using the propensity score matching the incidence of the primary endpoint was comparable in both groups.

Conclusion: The dose of a loop diuretic recommended to patients with acute heart failure at hospital discharge correlates well with the severity of heart failure. When comparing the groups of patients with a higher dose of furosemide (41-125 mg) and a lower dose of furosemide (10-40 mg) we found that after adjustment using propensity score matching the higher dose of loop diuretic had a neutral effect on the incidence of the composite endpoint of overall mortality and/or readmission for ADHF.

Keywords: Acute heart failure; AHEAD; Diuretic; Furosemide; Mortality; Rehospitalization

Received: September 19, 2017; Accepted: September 29, 2017; Published: June 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pavlušová M, Miklík R, Špaček R, Benešová K, Zeman K, Cohen-Solal A, et al.. Increased dose of diuretics correlates with severity of heart failure and renal dysfunction and does not lead to reduction of mortality and rehospitalizations due to acute decompensation of heart failure; data from AHEAD registry. Cor Vasa. 2018;60(3):e215-223. doi: 10.1016/j.crvasa.2017.09.007.
Download citation

References

  1. M.S. Nieminen, D. Brutsaert, K. Dickstein, et al., EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population, European Heart Journal 27 (2006) 2725-2736. Go to original source... Go to PubMed...
  2. J.S. Rossi, J.D. Flaherty, G.C. Fonarow, et al., Influence of coronary artery disease and coronary revascularization status on outcomes in patients with acute heart failure syndromes: a report from OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure), European Journal of Heart Failure 10 (2008) 1215-1223. Go to original source... Go to PubMed...
  3. K. Siirilä-Waris, J. Lassus, J. Melin, et al., Characteristics, outcomes, and predictors of 1-year mortality in patients hospitalized for acute heart failure, European Heart Journal 27 (2006) 3011-3017. Go to original source... Go to PubMed...
  4. J. Spinar, J. Parenica, J. Vitovec, et al., Baseline characteristics and hospital mortality in the Acute Heart Failure Database (AHEAD) Main registry, Critical Care (London, England) 15 (2011) R291. Go to original source... Go to PubMed...
  5. J. Spinar, J. Jarkovsky, L. Spinarova, et al., AHEAD score - long-term risk classification in acute heart failure, International Journal of Cardiology 202 (2016) 21-26. Go to original source... Go to PubMed...
  6. M.S. Nieminen, K. Dickstein, C. Fonseca, et al., The patient perspective: quality of life in advanced heart failure with frequent hospitalisations, International Journal of Cardiology 191 (2015) 256-264. Go to original source... Go to PubMed...
  7. J.J.V. McMurray, S. Adamopoulos, S.D. Anker, et al., ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC, European Heart Journal 33 (14) (2012) 1787-1847. Go to original source... Go to PubMed...
  8. R. Faris, M. Flather, H. Purcell, et al., Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials, International Journal of Cardiology 82 (2002) 149-158. Go to original source... Go to PubMed...
  9. M. Arrigo, E. Gayat, J. Parenica, et al., Precipitating factors and 90-day outcome of acute heart failure: a report from the intercontinental GREAT registry, European Journal of Heart Failure 19 (2) (2017) 201-208. Go to original source... Go to PubMed...
  10. G.S. Francis, R.M. Siegel, S.R. Goldsmith, et al., Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis, Annals of Internal Medicine 103 (1985) 1-6. Go to original source... Go to PubMed...
  11. J. Bayliss, M. Norell, R. Canepa-Anson, et al., Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics, British Heart Journal 57 (1987) 17-22. Go to original source... Go to PubMed...
  12. M. Domanski, J. Norman, B. Pitt, et al., Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD), Journal of the American College of Cardiology 42 (2003) 705-708. Go to original source... Go to PubMed...
  13. G.W. Neuberg, A.B. Miller, C.M. O'Connor, et al., Diuretic resistance predicts mortality in patients with advanced heart failure, American Heart Journal 144 (2002) 31-38. Go to original source... Go to PubMed...
  14. S. Eshaghian, T.B. Horwich, G.C. Fonarow, Relation of loop diuretic dose to mortality in advanced heart failure, American Journal of Cardiology 97 (12) (2006) 1759-1764. Go to original source... Go to PubMed...
  15. A. Ahmed, J.B. Young, T.E. Love, et al., A propensity-matched study of the effects of chronic diuretic therapy on mortality and hospitalization in older adults with heart failure, International Journal of Cardiology 125 (2008) 246-253. Go to original source... Go to PubMed...
  16. A. Ahmed, A. Husain, T.E. Love, et al., Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods, European Heart Journal 27 (2006) 1431-1439. Go to original source... Go to PubMed...
  17. P. Pellicori, J.G. Cleland, J. Zhang, et al., Cardiac dysfunction, congestion and loop diuretics: their relationship to prognosis in heart failure, Cardiovascular Drugs and Therapy 30 (2016) 599-609. Go to original source... Go to PubMed...
  18. M.S. Nieminen, M. Böhm, M.R. Cowie, et al., Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology, European Heart Journal 26 (2005) 384-416. Go to original source...
  19. J. Parenica, J. Spinar, J. Vitovec, et al., Long-term survival following acute heart failure: the Acute Heart Failure Database Main registry (AHEAD Main), European Journal of Internal Medicine 24 (2013) 151-160. Go to original source... Go to PubMed...
  20. S. Littnerova, J. Parenica, J. Spinar, et al., Positive influence of being overweight/obese on long term survival in patients hospitalised due to acute heart failure, PLOS ONE 10 (2015) e0117142. Go to original source... Go to PubMed...
  21. P. Ponikowski, A.A. Voors, S.D. Anker, et al., 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC, European Heart Journal 37 (2016) 2129-2200. Go to original source... Go to PubMed...
  22. M.B. Yilmaz, E. Gayat, R. Salem, et al., Impact of diuretic dosing on mortality in acute heart failure using a propensity-matched analysis, European Journal of Heart Failure 13 (2011) 1244-1252. Go to original source... Go to PubMed...
  23. B. Pitt, W. Remme, F. Zannad, et al., Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction, New England Journal of Medicine 348 (2003) 1309-1321. Go to original source... Go to PubMed...
  24. B. Pitt, F. Zannad, W.J. Remme, et al., The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators, New England Journal of Medicine 341 (10) (1999) 709-717. Go to original source... Go to PubMed...
  25. S. Bangalore, S. Kumar, F.H. Messerli, When conventional heart failure therapy is not enough: angiotensin receptor blocker, direct renin inhibitor, or aldosterone antagonist?, Congestive Heart Failure (Greenwich, Conn.) 19 (2013) 107-115. Go to original source... Go to PubMed...
  26. J.C. Trullàs, J.L. Morales-Rull, J. Casado, et al., Rationale and Design of the "Safety and Efficacy of the Combination of Loop with Thiazide-type Diuretics in Patients with Decompensated Heart Failure (CLOROTIC) Trial": A Double-Blind, Randomized, Placebo-Controlled Study to Determine the Effect of Combined Diuretic Therapy (Loop Diuretics With Thiazide-Type Diuretics) Among Patients With Decompensated Heart Failure, Journal of Cardiac Failure 22 (2016) 529-536. Go to original source... Go to PubMed...
  27. J.C. Jentzer, T.A. DeWald, A.F. Hernandez, Combination of loop diuretics with thiazide-type diuretics in heart failure, Journal of the American College of Cardiology 56 (2010) 1527-1534. Go to original source... Go to PubMed...
  28. H.A. Cooper, D.L. Dries, C.E. Davis, et al., Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction, Circulation 100 (1999) 1311-1315. Go to original source... Go to PubMed...




Cor et Vasa

You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.